Prostatectomy versus watchful waiting in patients with localized prostate cancer: the survival benefit can be spotted in the long run
In the United States, prostate cancer (PCa) remains the most common non-skin malignancy in men, with an estimation of 174,650 new cases and 31,620 deaths likely to occur in 2019 (1). Nowadays, 80% of PCa is localized to the prostate at the time of diagnosis (2). Active treatment for these patients includes radical prostatectomy (RP), radiation therapy, and active surveillance in very low and low risk disease (3). At the time no definitive data exists regarding the best treatment option for localized PCa and it should be discussed with every patient on the basis of disease characteristics (4).